Chiron Corporation

Chiron Corporation was an American biotechnology company founded in 1981 by University of California scientists William J. Rutter, Edward Penhoet, and Pablo D. T. Valenzuela. Based in Emeryville, California, the company developed a business model centered on molecular biology, genetic engineering, licensing relationships, and partnerships with larger pharmaceutical and healthcare companies. Its activities eventually covered three principal areas: biopharmaceuticals, vaccines, and blood testing. The company became particularly important in hepatitis research. In 1987, Chiron researchers produced a genetically engineered hepatitis B vaccine, and in 1989 a Chiron-led research team identified the hepatitis C virus in collaboration with investigators at the U.S. Centers for Disease Control and Prevention. The hepatitis C discovery supported a broad portfolio of patents, diagnostic technologies, and commercial relationships, including the development of nucleic-acid testing for donated blood. Chiron expanded through alliances, acquisitions, and mergers. Its combination with Cetus Corporation added oncology and biotechnology capabilities, while later purchases brought products and businesses in vaccines, inhaled antibiotics, diagnostics, and cancer therapeutics. The company acquired PathoGenesis in 2001, adding TOBI, an inhaled antibiotic used for lung infections associated with cystic fibrosis, and bought PowderJect in 2003, strengthening its position in vaccines. Chiron also built a large influenza-vaccine business through the development of Fluad and the acquisition of European vaccine operations from Behring and Sclavo. Its blood-testing business developed in cooperation with Gen-Probe. The resulting Procleix system used nucleic-acid testing to detect viral genetic material in donated blood and plasma at an earlier stage than conventional immunodiagnostic methods. Chiron Diagnostics was later sold to Bayer, while other operations were reorganized into specialized divisions covering oncology, vaccines, diagnostics, ophthalmology, and research technologies. Chiron experienced legal disputes involving polymerase-chain-reaction rights, hepatitis C patents, and the sale of its diagnostics operations. Its most serious operational crisis came in 2004, when United Kingdom regulators suspended the license for manufacturing Fluvirin at the company's Liverpool facility over contamination concerns. The suspension disrupted vaccine supplies in the United States and led to litigation and extensive remediation. The manufacturing license was restored in 2005, but the episode damaged the company's reputation and complicated its strategic position. Novartis, which had owned a substantial minority interest in Chiron, made an acquisition offer in 2005. After the offer was increased, Chiron accepted, and the acquisition was completed on April 20, 2006. Its vaccine and blood-testing activities were combined within Novartis Vaccines and Diagnostics, while the biopharmaceutical operations were integrated into Novartis Pharmaceuticals. Novartis subsequently divested substantial portions of the former Chiron businesses, including the blood-transfusion diagnostics unit and the vaccines business. Chiron therefore no longer exists as an independent corporate brand, although technologies and products developed under its name continued within successor organizations.

Chiron was founded in 1981 in California by William J. Rutter, Edward Penhoet, and Pablo D. T. Valenzuela, all associated with the University of California. The founders built the company around molecular biology and genetic engineering rather than a large traditional manufacturing infrastructure. Early strategy emphasized specialized markets, technology licensing, and partnerships with established pharmaceutical companies. Chiron worked with Ciba-Geigy through the Biocine venture and formed additional collaborations related to vaccines, wound-healing therapies, and infectious-disease research. During the 1980s, Chiron concentrated substantial research resources on viral hepatitis. In 1987, its researchers produced a commercial genetically engineered hepatitis B vaccine. In 1989, Chiron scientists Michael Houghton, Qui-Lim Choo, and George Kuo, working with Daniel Bradley of the CDC, identified the hepatitis C virus. The discovery became the scientific foundation for diagnostic tests and a large patent portfolio. It also positioned Chiron as an important supplier of enabling technologies to other companies. The company expanded during the late 1980s and 1990s. It formed Mimesys with Johnson & Johnson and Warner-Lambert, recruited Gregory Lawless as chief executive, acquired or partnered with diagnostic and biotechnology businesses, and merged with Cetus Corporation. After the Cetus transaction, Chiron organized its activities into separate businesses, including Cetus Oncology, Biocine vaccines, Chiron Diagnostics, Chiron Intraoptics, and Chiron Technologies. Its products included Proleukin for cancer treatment, Betaseron for relapsing-remitting multiple sclerosis, and the becaplermin active ingredient used in Regranex for diabetic foot ulcers. Vaccines became one of Chiron's largest areas. The company launched Fluad in 1996 and expanded in Europe through the acquisition of vaccine businesses associated with Behring and Sclavo in 1998. In 2003, it acquired PowderJect, a British vaccine company, making Chiron one of the world's largest influenza-vaccine suppliers. Its portfolio included Fluvirin, Agrippal, Begrivac, and RabAvert/Rabipur, and it manufactured the MMR vaccine at its Liverpool facility. Chiron also worked with Crucell on Quinvaxem, a combination childhood vaccine. Blood testing was another major pillar. In cooperation with Gen-Probe, Chiron launched a nucleic-acid testing business in 1998 and introduced the Procleix system in 1999. The system was designed to detect viral RNA and DNA in donated blood and plasma earlier than conventional immunodiagnostic methods. Chiron Diagnostics was later sold to Bayer for a reported transaction value of $1.1 billion; because this is a historical financial figure, it is retained only with the cited source context in the relevant transaction record. Chiron's growth also generated legal disputes. A lawsuit involving Eastman Kodak over polymerase-chain-reaction rights was settled after the Cetus acquisition. Chiron later sued Roche over hepatitis C patents and ultimately agreed to sell Roche global semi-exclusive nucleic-acid-testing patent rights for hepatitis C and HIV. Bayer separately sued Chiron over alleged problems and disclosures connected with the acquisition of Chiron Diagnostics. The company's most damaging crisis occurred in 2004. The UK Medicines and Healthcare products Regulatory Agency suspended the Liverpool manufacturing license for Fluvirin after contamination concerns, including the possibility that millions of doses were affected by Serratia marcescens. The suspension contributed to a shortage of influenza vaccine in the United States. Chiron entered a remediation program and regained the license in 2005. A related shareholder class action alleged that Chiron and executives had overstated Fluvirin production and shipment capabilities; the litigation was settled in 2008 for $30 million. Novartis had acquired a significant minority stake in Chiron before making a full takeover offer in 2005. After Chiron rejected an initial proposal, Novartis increased the offer and completed the acquisition on April 20, 2006. Chiron's vaccine and blood-testing businesses became part of Novartis Vaccines and Diagnostics, while its biopharmaceutical operations were integrated into Novartis Pharmaceuticals. Novartis later sold or reorganized much of the former Chiron portfolio, including the blood-transfusion diagnostics unit, which was sold to Grifols in 2014, and the vaccines business, for which agreements with GlaxoSmithKline were announced in the same period.

1. 2014Former Chiron units divested

   Novartis completed or announced major divestments involving former Chiron blood-testing and vaccine operations.

   Source
2. 2006Acquired by Novartis

   Novartis completed its acquisition of Chiron on April 20, 2006.

   Source
3. 2004Fluvirin manufacturing crisis

   UK regulators suspended the Liverpool license for Fluvirin manufacturing because of contamination concerns.

   Source
4. 2003PowderJect acquisition

   The acquisition of PowderJect expanded Chiron's vaccine operations and increased its influenza-vaccine scale.

   Source
5. 2001PathoGenesis acquisition

   Chiron acquired PathoGenesis and added TOBI to its biopharmaceutical portfolio.

   Source
6. 1999Procleix system launches

   Chiron and Gen-Probe introduced Procleix nucleic-acid testing for donated blood and plasma.

   Source
7. 1998European vaccine expansion

   Chiron acquired European vaccine businesses associated with Behring and Sclavo.

   Source
8. 1996Fluad launches

   Chiron launched its first vaccine product, the adjuvanted influenza vaccine Fluad.

   Source
9. 1991Cetus combination

   Chiron acquired or merged with Cetus Corporation, adding oncology and biotechnology capabilities.

   Source
10. 1989Hepatitis C virus identified

    Chiron scientists and CDC collaborators identified the virus responsible for most non-A, non-B post-transfusion hepatitis.

    Source
11. 1987Genetically engineered hepatitis B vaccine

    Chiron researchers produced the first commercial genetically engineered hepatitis B vaccine.

    Source
12. 1981Chiron is founded

    William J. Rutter, Edward Penhoet, and Pablo D. T. Valenzuela founded Chiron as a biotechnology company in California.

    Source

A research-driven biotechnology company combining genetic engineering, vaccine development, blood safety testing, and pharmaceutical partnerships.

• FluadInfluenza vaccine1996

  Fluad was Chiron's adjuvanted influenza vaccine, launched in 1996. It represented the beginning of the company's major expansion into influenza immunization and helped establish Chiron as a significant vaccine producer.

• FluvirinInfluenza vaccine

  Fluvirin was an influenza vaccine manufactured by Chiron, including at its Liverpool facility. It became the focus of a major 2004 regulatory crisis after UK authorities suspended the manufacturing license because of contamination concerns.

• ProcleixBlood-screening diagnostics1999

  Procleix was a nucleic-acid testing system developed with Gen-Probe. It was designed to identify viral RNA and DNA in donated blood and plasma during early infection, complementing conventional immunodiagnostic testing.

• TOBIInhaled antibiotic

  TOBI was an inhaled antibiotic for lung infections in patients with cystic fibrosis. Chiron obtained the product through its 2001 acquisition of PathoGenesis, expanding its biopharmaceutical business beyond vaccines and diagnostics.

• ProleukinOncology biopharmaceutical1992

  Proleukin, an interleukin-2 therapy, became Chiron's first product approved in the United States. It was approved in 1992 for metastatic melanoma and had previously been approved for kidney cancer.

• RabAvert/RabipurRabies vaccine

  RabAvert and Rabipur were rabies-vaccine brands associated with Chiron's vaccine portfolio. They formed part of the company's broader human-vaccine business alongside influenza and combination childhood vaccines.

• AgrippalInfluenza vaccine

  Agrippal was one of the influenza-vaccine products in Chiron's European portfolio, developed and marketed within the company's expanded vaccine operations.

• BegrivacInfluenza vaccine

  Begrivac was an influenza-vaccine brand associated with the European vaccine businesses acquired by Chiron. It contributed to Chiron's position as a major international influenza-vaccine supplier.

• 2014Divest former Chiron diagnostics and vaccine businessesStrategy

  Novartis reorganized its healthcare portfolio several years after acquiring Chiron.

  What changed. Novartis completed the sale of its blood-transfusion diagnostics unit to Grifols and announced agreements concerning the sale of its vaccines unit to GlaxoSmithKline.

  Aftermath. Most major operating businesses inherited from Chiron moved to other corporate owners, further ending the practical use of Chiron as an operating brand.

  Source
• 2005Accept Novartis takeover offerM&A

  Novartis already held a substantial minority interest in Chiron and sought full ownership after Chiron initially rejected an offer.

  What changed. Chiron accepted an enhanced Novartis offer, leading to completion of the acquisition in April 2006.

  Aftermath. Chiron ceased to operate as an independent company and its businesses were integrated into Novartis divisions.

  Source
• 2003Acquire PowderJectM&A

  Chiron was expanding its vaccine manufacturing and international distribution capabilities.

  What changed. It acquired PowderJect, a UK-based vaccine company.

  Aftermath. Chiron became the second-largest influenza-vaccine provider and the fifth-largest vaccine business globally, according to the referenced company history.

  Source
• 2001Acquire PathoGenesisM&A

  Chiron wanted to broaden its biopharmaceutical portfolio beyond oncology and vaccine products.

  What changed. It acquired PathoGenesis and obtained TOBI, an inhaled antibiotic for cystic-fibrosis-related lung infections.

  Aftermath. The transaction strengthened Chiron's specialty biopharmaceutical business.

  Source
• 1998Build a nucleic-acid blood-testing businessStrategy

  Chiron sought to apply its molecular-biology capabilities to blood safety and early detection of viral infections.

  What changed. It partnered with Gen-Probe to develop and commercialize nucleic-acid testing for donated blood and plasma.

  Aftermath. The partnership produced the Procleix system and made blood screening one of Chiron's three principal business areas.

  Source

• 2008Fluvirin-related shareholder litigation settlementControversy

  A class action alleged that Chiron and company executives had overstated the company's ability to manufacture and ship Fluvirin before the Liverpool plant shutdown. The litigation was settled in 2008 for $30 million.

  Source
• 2004Fluvirin contamination and manufacturing-license suspensionControversy

  The UK regulator suspended Chiron's license to manufacture Fluvirin at its Liverpool plant after contamination concerns, including reports that millions of doses might have been affected by Serratia marcescens. The action contributed to an influenza-vaccine shortage in the United States and led to remediation, regulatory scrutiny, and shareholder litigation.

  Source

• 2006Novartis completes acquisition of Chiron

  Novartis completed its acquisition of Chiron on April 20, ending Chiron's existence as an independent biotechnology company.

  M&A
  Source
• 2003Bombs explode at Chiron headquarters

  Two bombs exploded at Chiron's Emeryville headquarters. A group calling itself Revolutionary Cells claimed responsibility and linked the action to Chiron's contracts with Huntingdon Life Sciences.

  Other
  Source
• 2001Chiron acquires PathoGenesis

  The acquisition added TOBI, an inhaled antibiotic used in the treatment of lung infections associated with cystic fibrosis.

  M&AProduct launch
  Source
• 1998Chiron launches nucleic-acid blood testing with Gen-Probe

  The company and Gen-Probe established a blood-testing business based on nucleic-acid technology for detecting viral material in donated blood.

  Product launch
  Source
• 1996Chiron launches Fluad

  Chiron introduced Fluad, an adjuvanted influenza vaccine that became an important part of its expanding vaccine portfolio.

  Product launch
  Source
• 1989Chiron researchers identify the hepatitis C virus

  A Chiron-led research team, working with CDC collaborators, identified the viral agent responsible for most cases of non-A, non-B post-transfusion hepatitis.

  Product launchOther
  Source

1. Chiron Corporation